Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 30, 2005. The report details a share repurchase transaction executed under shareholder authority granted at the Annual General Meeting on May 17, 2004, and discloses changes in directors' interests in the company's ordinary shares.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 815,000 ordinary shares.
- Purchase Price: 1,221.1729 pence per share.
- Treasury Holdings: 85,518,000 shares held in Treasury following the purchase.
- Shares in Issue: 5,854,892,743 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the repurchase of 815,000 shares on March 30, 2005. Additionally, minor changes in directors' interests were recorded:
- Mr. J D Coombe and Mrs. G A Coombe acquired beneficial interests in 9 and 7 shares respectively via a Personal Equity Plan on March 29, 2005.
- The GSK Trust transferred 2,991 shares to participants in the SmithKline Beecham Employee Share Option Plan 1991 on March 29, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the total cost of the 815,000 share repurchase against the stated price of 1,221.1729 pence per share.
- Confirm the updated total share count (5,854,892,743 in issue) and Treasury holdings (85,518,000) in subsequent filings.
- Note that this filing is a routine disclosure of capital actions and director transactions, not a financial performance report.